MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025)

MapLight Therapeutics (MPLT) reported Depreciation & Amortization (CF) of $200000.0 for Q4 2025, little changed on a YoY basis from $201000.0 in Q4 2024, and up 100.0% sequentially from $100000.0 in Q3 2025.

MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Depreciation & Amortization (CF) data on file, last reported at $200000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed 0.5% year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $701000.0 (changed N/A YoY), and the FY2025 full-year result was $600000.0, down 14.41% from the prior year.
  • Depreciation & Amortization (CF) rose to $200000.0 in Q4 2025, from $100000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $201000.0 in Q4 2024 to a low of $100000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 196,658.72
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 41.14 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 55.90 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 123.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 2.20 Mn
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - 200,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 200,000.00
Dec 31, 2025 200,000.00
Sep 30, 2025 100,000.00
Sep 30, 2025 100,000.00
Dec 31, 2024 201,000.00
Dec 31, 2024 201,000.00
Sep 30, 2024 200,000.00
Sep 30, 2024 200,000.00